Ours Is a New
Way of Looking

Featured Items

Ataluren (PTC124^®) is an investigational new drug designed to enable the formation of a functioning protein in patients with genetic disorders due to a nonsense mutation. Learn about ataluren for genetic disorders

GEMS^™ (Gene Expression Modulation by Small-Molecules) is a novel and proprietary screening technology for the identification of small molecules. Learn about the GEMS^™ advantage

Our Pipeline

PTC's current pipeline of clinical and preclinical product candidates addresses multiple indications, including genetic disorders, oncology and infectious diseases.Learn about our therapeutic areas

patient stories

Click here to read patient stories about living with a rare disorder.

5/16/2013PTC Therapeutics, Inc. Files Registration Statement For Proposed Initial Public Offering

4/23/2013PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer

3/7/2013PTC Therapeutics Closes $60 Million Private Financing

View all latest news